Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab

Transplant Immunology

Volumn 24, Issue 3, 2011, Pages 142-148

  Ge, Shili ^a   Pao, Andy ^a   Vo, Ashley ^a   Deer, Nathan ^a   Karasyov, Artur ^a   Petrosyan, Anna ^a   Kahwaji, Joseph ^a   Lukovsky, Marina ^a   Chai, Ning Ning ^a   Aguiluz, Angela ^a   Mirocha, James ^a   Jordan, Stanley C ^a   Toyoda, Mieko ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab; Desensitization; Intravenous immunoglobulin (IVIG); Kidney transplantation; Rituximab; Safety

Indexed keywords

ALEMTUZUMAB; BIOGEN IDEC; DACLIZUMAB; GANCICLOVIR; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE FUNCTION; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; B-LYMPHOCYTES; CYTOMEGALOVIRUS INFECTIONS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; MONITORING, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 79951509265     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.11.006     Document Type: Article

References (35)

1. Jordan S., Cunningham-Rundles C., McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003, 3:653-664.
2. Jordan S.C., Tyan D., Stablein D., McIntosh M., Rose S., Vo A., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004, 15:3256-3262.
3. Vo A.A., Lukovsky M., Toyoda M., Wang J., Reinsmoen N.L., Lai C.H., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008, 359:242-251.
4. Vo A.A., Peng A., Toyoda M., Kahwaji J., Cao K., Lai C.H., et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010, 89:1095-1102.
5. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
6. Goldblatt F., Isenberg D.A. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus. Handb Exp Pharmacol 2008, 163-181.
7. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
8. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50:3580-3590.
9. Becker Y.T., Becker B.N., Pirsch J.D., Sollinger H.W. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004, 4:996-1001.
10. Fehr T., Rusi B., Fischer A., Hopfer H., Wuthrich R.P., Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009, 87:1837-1841.
11. Mulley W.R., Hudson F.J., Tait B.D., Skene A.M., Dowling J.P., Kerr P.G., et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009, 87:286-289.
12. Munoz A.S., Rioveros A.A., Cabanayan-Casasola C.B., Danguilan R.A., Ona E.T. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc 2008, 40:2218-2221.
13. Kaposztas Z., Podder H., Mauiyyedi S., Illoh O., Kerman R., Reyes M., et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009, 23:63-73.
14. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
15. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400.
16. Harting R., Venugopal P., Gregory S.A., O'Brien T., Bogdanova E. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007, 7:406-412.
17. Kamar N., Mengelle C., Rostaing L. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant 2009, 9:244-245.
18. Kamar N., Milioto O., Puissant-Lubrano B., Esposito L., Pierre M.C., Mohamed A.O., et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010, 15:3426-3430.
19. Pondrom S. The AJT report: news and issues that affect organ and tissue transplantation. Wrestling with positive cross-matches. A look at some of the newer desensitization therapies. Am J Transplant 2010, 10:2-4.
20. Vo A.A., Wechsler E.A., Wang J., Peng A., Toyoda M., Lukovsky M., et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 2008, 8:144-149.
21. Radha R, Jordan S, Puliyanda D, Bunnapradist S, Petrosyan A, Amet N, et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant. 2005/01/08 ed2005. p. 110-7.
22. Toyoda M., Zhang X., Petrosian A., Galera O.A., Wang S.J., Jordan S.C. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994, 14:178-189.
23. Toyoda M., Puliyanda D.P., Amet N., Baden L., Cam V., Radha R., et al. Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation 2005, 80:198-205.
24. Toyoda M., Moudgil A., Warady B.A., Puliyanda D.P., Jordan S.C. Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients. Pediatr Transplant 2008, 12:778-784.
25. Moudgil A., Nast C.C., Bagga A., Wei L., Nurmamet A., Cohen A.H., et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int 2001, 59:2126-2133.
26. Feuchtenberger M., Muller S., Roll P., Waschbisch A., Schafer A., Kneitz C., et al. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J 2008, 2:81-88.
27. Nakou M., Katsikas G., Sidiropoulos P., Bertsias G., Papadimitraki E., Raptopoulou A., et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009, 11:R131.
28. Stasi R., Cooper N., Del Poeta G., Stipa E., Evangelista ML, Abruzzese E., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008, 112:1147-1150.
29. Liossis S.N., Sfikakis P.P. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008, 127:280-285.
30. Hoyer B.F., Moser K., Hauser A.E., Peddinghaus A., Voigt C., Eilat D., et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004, 199:1577-1584.
31. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
32. Zeevi A., Husain S., Spichty K.J., Raza K., Woodcock J.B., Zaldonis D., et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 2007, 7:471-475.
33. Clatworthy M.R., Friend P.J., Calne R.Y., Rebello P.R., Hale G., Waldmann H., et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation 2009, 87:1092-1095.
34. Malek S.K., Obmann M.A., Gotoff R.A., Foltzer M.A., Hartle J.E., Potdar S. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006, 81:17-20.
35. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.